| Title |
Review of Models Used in Economic Analyses of New Oral Treatments for Type 2 Diabetes Mellitus
|
|---|---|
| Published in |
PharmacoEconomics, December 2013
|
| DOI | 10.1007/s40273-013-0117-7 |
| Pubmed ID | |
| Authors |
Carl V. Asche, Stephen E. Hippler, Dean T. Eurich |
| Abstract |
Economic models are considered to be important, as they help evaluate the long-term impact of diabetes treatment. To date, it appears that no article has reviewed and critically appraised the cost-effectiveness models developed to evaluate new oral treatments [glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors] for type 2 diabetes mellitus (T2DM). |
Mendeley readers
The data shown below were compiled from readership statistics for 116 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | <1% |
| United States | 1 | <1% |
| Unknown | 114 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 24 | 21% |
| Researcher | 23 | 20% |
| Student > Master | 16 | 14% |
| Other | 8 | 7% |
| Student > Doctoral Student | 7 | 6% |
| Other | 19 | 16% |
| Unknown | 19 | 16% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 42 | 36% |
| Pharmacology, Toxicology and Pharmaceutical Science | 15 | 13% |
| Economics, Econometrics and Finance | 8 | 7% |
| Biochemistry, Genetics and Molecular Biology | 4 | 3% |
| Nursing and Health Professions | 4 | 3% |
| Other | 19 | 16% |
| Unknown | 24 | 21% |
Attention Score in Context
This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 January 2021.
All research outputs
#3,421,307
of 23,576,969 outputs
Outputs from PharmacoEconomics
#335
of 1,880 outputs
Outputs of similar age
#40,950
of 309,488 outputs
Outputs of similar age from PharmacoEconomics
#5
of 26 outputs
Altmetric has tracked 23,576,969 research outputs across all sources so far. Compared to these this one has done well and is in the 84th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,880 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.0. This one has done well, scoring higher than 80% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 309,488 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 86% of its contemporaries.
We're also able to compare this research output to 26 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 84% of its contemporaries.